ANI Pharma (ANIP) Tops Q4 EPS by 8c

ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $0.76, $0.08 better than the analyst estimate of $0.68. Revenue for the quarter came in at $94.2 million versus the consensus estimate of $85.19 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Jefferies Reinstates Talen Energy (TLN) at Hold
• Prosperity Bancshares (PB) Reiterated at Overweight by Cantor Fitzgerald as Estimates Revised